Inhibiting AP-1 changes skin tumor types and affects tumor cell identity.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
Keratinocytes can reduce the survival of certain melanoma cells, suggesting new therapy paths.
1 citations
,
January 2010 in “Elsevier eBooks” Any drug can cause skin reactions, but antibiotics, NSAIDs, and psychotropic drugs are more common, with some reactions being life-threatening.
13 citations
,
August 2017 in “Journal of Cellular Physiology” PD‐L1 and PD‐L2 may not effectively control immune activation in alopecia areata.
6 citations
,
November 1977 in “International Journal of Legal Medicine” Human hair contains a substance that shows blood group A activity.
Alopecia areata is an autoimmune disease affecting hair follicles and may harm heart health.
33 citations
,
April 2003 in “Oncogene” 138 citations
,
January 2004 in “AIDS” Some HIV treatments can harm mitochondria, potentially causing side effects like lactic acidosis and nerve damage.
2 citations
,
January 2019 in “Annals of Dermatology” Certain gene variations in EGF and EGFR may increase the risk of alopecia areata in Koreans.
November 2022 in “Chinese Journal of Dermatology” Allergies, especially dust mite allergy, may worsen alopecia areata, and desensitization could help reduce its severity.
26 citations
,
June 2018 in “The journal of immunology/The Journal of immunology” AIRE-deficient rats developed severe autoimmune disease similar to APECED, useful for testing treatments.
1 citations
,
September 2023 in “Laboratornye Zhivotnye dlya nauchnych issledovanii (Laboratory Animals for Science)” Avian yolk antibodies offer a promising, ethical alternative for disease prevention and therapy.
April 2016 in “Journal of Investigative Dermatology” Tumor cell adhesion is linked to higher risk of SLN metastasis and melanoma recurrence, and a model including these factors predicts these outcomes better than one with just clinical data.
26 citations
,
September 2013 in “Journal of Dermatological Science” Serum granulysin levels can indicate the activity and prognosis of alopecia areata.
Hit15 shows promise as a COVID-19 treatment by reducing virus infection and inflammation.
1 citations
,
September 2019 in “Journal of Investigative Dermatology” Anti-Desmocollin 3 antibodies can cause pemphigus-like symptoms in mice.
7 citations
,
November 2006 in “Journal of immunological methods” The method can help diagnose and monitor diabetes by analyzing hair.
September 2025 in “Figshare” Alopecia areata involves complex immune activity, mainly Th1, with potential benefits from broader immune treatments.
28 citations
,
September 2008 in “Current Pharmaceutical Design” Allergic reactions to blood thinners are rare but can be serious, requiring careful management and alternative treatments.
4 citations
,
June 2025 in “Medeniyet Medical Journal” TMPRSS2 is crucial for COVID-19 infection and is a potential target for treatment.
4 citations
,
July 2014 in “The Journal of Dermatology” Plaque-type herpetic folliculitis affects eccrine glands.
2 citations
,
March 2022 in “PubMed” Most skin reactions to COVID-19 vaccines in India were mild and not a reason to avoid vaccination.
March 2005 in “Journal of the American Academy of Dermatology” Higher levels of IL-1a and IL-1RA were found in severe alopecia areata cases.
November 2024 in “Journal of Investigative Dermatology” Dermal IgA deposition without symptoms is rare in Dermatitis herpetiformis risk groups.
April 2026 in “World Allergy Organization Journal” Allergic rhinitis increases hair loss risk, but antihistamines can reduce it.
1 citations
,
May 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” PSA could be a marker for hyperandrogenism in women, but more research is needed.
26 citations
,
May 2020 in “JCI Insight” Alopecia areata involves specific immune cells, offering potential treatment targets.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” A new one-step test can quickly identify skin cancer during surgery.
11 citations
,
October 2001 in “Dermatologic Clinics” The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.